Merck to cut jobs

Merck plans to eliminate 7,200 jobs by the end of 2011, according to their 2008 third quarter linkurl:financial report,;http://www.merck.com/newsroom/press_releases/financial/2008_1022.html released today. The cuts are part of ongoing restructuring efforts and come after a 28% profit plunge in the third quarter. The restructuring efforts began in 2005, and at the time the linkurl:pharmaceutical company;http://www.the-scientist.com/article/display/23391/ eliminated more than 10,000 jobs. The c

Written byAndrea Gawrylewski
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Merck plans to eliminate 7,200 jobs by the end of 2011, according to their 2008 third quarter linkurl:financial report,;http://www.merck.com/newsroom/press_releases/financial/2008_1022.html released today. The cuts are part of ongoing restructuring efforts and come after a 28% profit plunge in the third quarter. The restructuring efforts began in 2005, and at the time the linkurl:pharmaceutical company;http://www.the-scientist.com/article/display/23391/ eliminated more than 10,000 jobs. The current cuts represent 10% of Merck's remaining job force; 40 % are US jobs, and a quarter of the cuts are of high-level or mid-level executive positions, although cuts will be made in every sector of the company. The company has suffered sluggish sales, especially of their vaccines, with third quarter revenue down 2%. Sales of prescription drugs between January and August of this year did not increase for the first time in 10 years, according to a linkurl:study;http://www.philly.com/philly/business/29553459.html by IMS Health. "With the right long-term strategy and our efforts to reshape Merck's business, including today's actions, I am confident we are building a solid foundation for achieving industry-leading performance in the future," Merck CEO Richard Clark said in the report.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies